TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,600,047 | -41.8% | 290,833 | -0.0% | 0.01% | -36.4% |
| Q2 2023 | $4,468,393 | -28.3% | 290,911 | +5.0% | 0.02% | -35.3% |
| Q1 2023 | $6,230,000 | +21.0% | 277,012 | +13.2% | 0.03% | +13.3% |
| Q4 2022 | $5,148,396 | -15.4% | 244,812 | -0.8% | 0.03% | -25.0% |
| Q3 2022 | $6,082,000 | +5.7% | 246,849 | +3.9% | 0.04% | +14.3% |
| Q2 2022 | $5,756,000 | -5.3% | 237,551 | +0.8% | 0.04% | +16.7% |
| Q1 2022 | $6,076,000 | -15.0% | 235,774 | +2.3% | 0.03% | -14.3% |
| Q4 2021 | $7,151,000 | +75.3% | 230,369 | +36.9% | 0.04% | +66.7% |
| Q3 2021 | $4,080,000 | +1107.1% | 168,250 | +1258.2% | 0.02% | +950.0% |
| Q4 2020 | $338,000 | – | 12,388 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |